CT/NG Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Assays And Kits, Instruments/Analyzers), By Testing Type (Lab Tests, PoC Tests), By Technology (Immunodiagnostics, Isothermal Nucleic Acid Amplification Technology, Polymerase Chain Reaction), By End User (Clinical Laboratories, Hospitals & Clinics, Others), By Region, and By Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 1.87 Billion
CAGR (2026-2031)	8.84%
Fastest Growing Segment	Assays and Kits
Largest Market	North America
Market Size (2031)	USD 3.11 Billion

Market Overview

The Global CT and NG Testing Market will grow from USD 1.87 Billion in 2025 to USD 3.11 Billion by 2031 at a 8.84% CAGR. The Global CT and NG Testing Market comprises diagnostic assays and instrument systems designed for the qualitative detection of Chlamydia trachomatis and Neisseria gonorrhoeae pathogens primarily utilizing nucleic acid amplification techniques. Market growth is fundamentally driven by the escalating global prevalence of these sexually transmitted infections and the expanding implementation of government-mandated screening initiatives. Furthermore the increasing integration of point-of-care testing methodologies in non-traditional healthcare settings accelerates the adoption of rapid diagnostic solutions by facilitating timely treatment and disease management.

One significant challenge impeding market expansion is the social stigma and asymptomatic nature of these diseases which frequently discourages individuals from seeking voluntary testing. This barrier limits effective case finding and reduces the utilization of diagnostic products in key demographics. Highlighting the persistent disease burden according to the National Coalition of STD Directors, in 2024, more than 2.2 million cases of chlamydia, gonorrhea, and syphilis were reported in the United States. This substantial volume of infections indicates a sustained demand for robust diagnostic testing infrastructure.

Key Market Drivers

The proliferation of direct-to-consumer and at-home self-collection kits is significantly expanding market access by circumventing the social stigma and logistical barriers associated with traditional clinic-based testing. This driver is democratizing diagnostic availability, allowing individuals to perform high-accuracy testing in private settings, which is crucial for capturing asymptomatic infections that might otherwise go undetected. Manufacturers are increasingly securing regulatory approvals for sophisticated molecular platforms designed for lay users, bridging the gap between professional lab accuracy and consumer convenience. According to Visby Medical, March 2025, in an announcement regarding regulatory achievements, the U.S. Food and Drug Administration granted De Novo authorization for their Women’s Sexual Health Test, establishing it as the first PCR diagnostic device approved for over-the-counter home use for the detection of chlamydia and gonorrhea.

Simultaneously, a technological shift toward high-sensitivity Nucleic Acid Amplification Tests and the integration of automated high-throughput systems are streamlining clinical workflows to meet sustained testing demand. Laboratories are prioritizing platforms that offer rapid turnaround times and consolidated menus to manage large sample volumes efficiently while maintaining high specificity. This operational efficiency is reflected in the financial performance of major industry players investing in molecular infrastructure. According to Roche, January 2025, in the 'Annual Report 2024', the Diagnostics Division achieved sales of CHF 14.3 billion, with the base business growing by 8 percent largely due to increased demand for immunodiagnostic and molecular solutions. This diagnostic capacity remains critical for public health monitoring; according to the UK Health Security Agency, in 2025, a total of 71,802 diagnoses of gonorrhea were recorded for the preceding year in England alone, underscoring the continued necessity for robust surveillance systems.

Download Free Sample Report

Key Market Challenges

The social stigma associated with sexually transmitted infections, combined with the frequently asymptomatic presentation of Chlamydia trachomatis and Neisseria gonorrhoeae, creates a substantial barrier to the growth of the diagnostic market. When individuals do not experience physical symptoms, they often lack the motivation to seek medical attention, while fear of societal judgment further deters voluntary screening. This hesitation directly reduces the volume of patient-initiated visits to healthcare providers, thereby decreasing the overall utilization of diagnostic assays and instrumentation. Consequently, manufacturers face a restricted market where testing is primarily reactive rather than preventative, significantly suppressing the potential volume of assay consumption.

The persistence of these undetected infections highlights the market impact of this screening gap. Because these pathogens spread silently, a vast number of potential testing opportunities are missed, limiting revenue streams for diagnostic providers and stalling market penetration in key demographics. Illustrating the severity of missed detection due to these barriers, according to the National Association of County and City Health Officials, in 2024, congenital syphilis cases increased by 2% to nearly 4,000 cases. This statistic demonstrates the critical failure to capture asymptomatic infections in a timely manner, underscoring how the hidden nature of these diseases fundamentally curtails the expansion of the global testing market.

Key Market Trends

The market is increasingly shifting toward multiplex syndromic testing panels, which facilitate the simultaneous detection of Chlamydia trachomatis, Neisseria gonorrhoeae, and prevalent co-infections such as Mycoplasma genitalium and Trichomonas vaginalis. This transition is driven by the clinical necessity to distinguish between pathogens with overlapping symptoms in a single patient visit, moving beyond the limitations of single-target assays to improve antimicrobial stewardship. The operational momentum behind this approach is evidenced by the robust commercial performance of major syndromic panel providers. According to BioMérieux, March 2025, in the '2024 Financial Results', sales of the company's BIOFIRE non-respiratory panels increased by 17%, illustrating the accelerating uptake of comprehensive infectious disease profiling in clinical workflows.

Parallel to the rise of syndromic panels, there is a distinct transition of molecular diagnostics into decentralized clinical settings such as urgent care centers and outpatient clinics. Unlike at-home testing or central laboratory processing, this trend focuses on the professional administration of rapid PCR tests at the point of care to enable immediate treatment protocols, thereby minimizing the rate of patients lost to follow-up. The physical footprint of this decentralized infrastructure has widened significantly as healthcare networks prioritize near-patient accessibility. According to Danaher, January 2025, in the 'Fourth Quarter 2024 Earnings Call Transcript', the global installed base of Cepheid molecular systems grew by high single digits to exceed 60,000 instruments, a milestone fueled largely by accelerated placements in alternate care sites beyond the traditional hospital laboratory.

Segmental Insights

The Assays and Kits segment represents the fastest-growing category within the Global CT and NG Testing Market, driven by the expanding adoption of molecular diagnostic techniques. This growth is primarily sustained by the recurring nature of consumable purchases required for high-volume screening programs intended to curb rising infection rates. As clinical laboratories face increasing demands for accurate testing, the consumption of these disposable reagents rises proportionately. Furthermore, frequent product clearances by regulatory authorities such as the US FDA continue to broaden the availability of verified testing options, thereby accelerating the commercial uptake of these essential diagnostic supplies.

Regional Insights

North America holds a dominant position in the Global CT and NG Testing Market, driven by high public health awareness and established healthcare infrastructure. The increasing incidence of sexually transmitted infections has led the Centers for Disease Control and Prevention to recommend routine screening programs, directly increasing testing demand. Additionally, the availability of molecular diagnostics and favorable reimbursement policies support market expansion. The region also benefits from the strong presence of major diagnostic manufacturers and frequent product approvals by the U.S. Food and Drug Administration, ensuring consistent accessibility to testing solutions.

Recent Developments

• In March 2025, Visby Medical obtained FDA De Novo authorization for its instrument-free, polymerase chain reaction (PCR) test for women's sexual health, marketed for over-the-counter use. This approval marked the first time a home-use PCR device was authorized for the simultaneous detection of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis. The single-use device was designed to provide lab-accurate results in under 30 minutes from a self-collected vaginal swab, eliminating the need to mail samples to a facility. The company positioned this breakthrough as a significant advancement in increasing access to private, reliable diagnostic testing for common curable infections.
• In January 2025, Roche Diagnostics received FDA 510(k) clearance and a Clinical Laboratory Improvement Amendments (CLIA) waiver for its new multiplex assay panels designed to detect sexually transmitted infections at the point of care. The regulatory approval covered tests for Chlamydia trachomatis and Neisseria gonorrhoeae, utilizing the company's compact cobas liat system. This milestone allowed healthcare providers in decentralized settings, such as urgent care clinics and physician offices, to perform rapid molecular testing with results available in approximately 20 minutes. The launch aimed to facilitate immediate clinical decisions and reduce the loss to follow-up often associated with central laboratory testing.
• In January 2025, Abbott Laboratories secured FDA 510(k) clearance for a novel self-collection kit intended for use with its high-volume molecular diagnostic system. The clearance authorized the use of the Simpli-COLLECT STI Test, which allows individuals to self-collect urogenital specimens in home settings for the subsequent detection of Chlamydia trachomatis, Neisseria gonorrhoeae, and other pathogens in a laboratory. This development was designed to improve patient privacy and testing accessibility by integrating remote collection with the company's automated Alinity m platform, addressing the growing demand for convenient screening options while maintaining the high sensitivity associated with centralized molecular diagnostics.
• In February 2024, binx health entered into a national distribution agreement with Cardinal Health to expand access to its rapid molecular point-of-care testing platform. This strategic collaboration focused on broadening the availability of the FDA-cleared, CLIA-waived binx io system, which detects Chlamydia trachomatis and Neisseria gonorrhoeae, across acute care settings such as urgent care centers, primary care offices, and retail pharmacies in the United States. The partnership leveraged the distributor’s extensive logistics network to facilitate wider adoption of the platform, which enables clinicians to provide central laboratory-quality results and appropriate treatment during a single patient visit.

Key Market Players

• F. Hoffmann-La Roche Ltd.
• Hologic, Inc.
• Thermo Fisher Scientific Inc.
• Abbott Laboratories Inc.
• QIAGEN N.V.
• PerkinElmer Inc.
• Bio-Rad Laboratories, Inc.
• Siemens Healthineers AG
• Danaher Corporation
• Becton, Dickinson, and Company

By Product	By Testing Type	By Technology	By End User	By Region
Assays And Kits Instruments/Analyzers	Lab Tests PoC Tests	Immunodiagnostics Isothermal Nucleic Acid Amplification Technology Polymerase Chain Reaction	Clinical Laboratories Hospitals & Clinics Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global CT and NG Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• CT and NG Testing Market, By Product:

• Assays And Kits
• Instruments/Analyzers

• CT and NG Testing Market, By Testing Type:

• Lab Tests
• PoC Tests

• CT and NG Testing Market, By Technology:

• Immunodiagnostics
• Isothermal Nucleic Acid Amplification Technology
• Polymerase Chain Reaction

• CT and NG Testing Market, By End User:

• Clinical Laboratories
• Hospitals & Clinics
• Others

• CT and NG Testing Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE